Robin Forrest

Research Fellow @DeptPopMed / @HarvardMed || PhD candidate @LSEHealthPolicy

[Robin Forrest @robinjforrest_]

New paper in @TheLancetOncol.

We explore the extent to which individuals could be willing to wait in exchange for greater certainty of the survival benefit of new cancer drugs.

Thanks to co-auths: @mylene_lagarde, @AggarwalOnc, & Huseyin Naci.

🔗https://t.co/lw3KPBTcZy

[JAMA Network Open @JAMANetworkOpen]

Patients with #BreastCancer considered faster drug approval acceptable mainly when no alternatives existed or anticipated benefits were transformative, preferring certainty when options are available.

https://t.co/7MC2i6RpOR

[Robin Forrest @robinjforrest_]

Interesting piece from @VPrasadMDMPH on surrogate endpoints and their (potential) impact on efficiency and the cancer drug pipeline.

Good to see our study discussed in context!

[Vinay Prasad MD MPH @VPrasadMDMPH]

Just out in @NatRevClinOncol my latest on Surrogate Endpoints from the patient's perspective
Despite writing on this topic for 15 years, hope to offer new ideas in this piece
@vkprasadlab @Sensible__Med @Plenary_Session

[Robin Forrest @robinjforrest_]

@coloncanada @oncology_bg As one of the authors of the study, I could not agree with your statement more @coloncanada.

Context, balance, and nuance are essential for interpreting our findings, which we provide in the paper but are not always conveyed in one-sentence summaries.

[LSE Health Policy @LSEHealthPolicy]

To what extent would individuals be willing to wait in exchange for greater certainty of the survival benefit of new cancer drugs?

New study in @TheLancetOncol by @robinjforrest_, @mylene_lagarde, @AggarwalOnc, & Dr. Huseyin Naci.

Read now🔗https://t.co/Sd5kU3kMWK

[LSE @LSEnews]

NEW 💊 Cancer patients could be willing to wait for certainty of the benefit of cancer drugs before they're approved by the FDA.

More on @TheLancetOncol #CancerResearch by @robinjforrest_ & Huseyin Naci @LSEHealthPolicy & @mylene_lagarde @AggarwalOnc.
https://t.co/fwe6z4VMWD

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

A very relevant and meaningful study. Understanding patients’ preferences for speed versus certainty of benefit- the trade-off of accelerated approval.

[Adam Raymakers @AdamR_PhD]

Interesting new work from authors @LSEHealthPolicy!

'Although people with experience of cancer place high value on faster access to new drugs, they also place utmost value on high certainty that new cancer drugs will ultimately offer survival benefit.'

https://t.co/myGTr7rdQp

[The Lancet Oncology @TheLancetOncol]

Online First:

Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discrete choice experiment

https://t.co/saTfZIL4px

[Kristina Jenei @kjmeetswrld]

🚨Our article out today in @TheLancetOncol

Are countries harmonizing up or down?

A 🧵

We examine the clinical benefit, #HTA review times, and prices of drugs reviewed through Project Orbis

Cc: @VPrasadMDMPH @agentilini_ @AlysonHaslam

[The Lancet Oncology @TheLancetOncol]

Also Online First:

#Overallsurvival benefits of #cancerdrugs initially approved by the US Food and Drug Administration @US_FDA on the basis of immature survival data: a retrospective analysis
https://t.co/zgPUDWoSC7

[LSE Health Policy @LSEHealthPolicy]

In a new @bmj_latest editorial, the department’s @robinjforrest_ and Huseyin Naci discuss how the UK Government can prioritise patients in ongoing negotiations with the pharmaceutical industry over drug pricing.

Access full editorial from here:
➡️ https://t.co/31zX5hvxNY

[The BMJ @bmj_latest]

Every five years or so, an agreement is brokered between the UK government and the drug industry that shapes the pricing and reimbursement landscape for medicines.

What do we need to know ahead of negotiations for the next version of the agreement?
https://t.co/3FyMOu7r6x

[JAMA Health Forum @JAMAHealthForum]

Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. @LSEHealthPolicy @PortalResearch @akesselheim @robinjforrest_ https://t.co/cZHnHts45L

[The Health Foundation @HealthFdn]

NEW: Our #REALCentre commissioned @LSEHealthPolicy to research pharmaceutical policy in the UK.

They identify 🔎
▶️ shortcomings of current pharmaceutical policy
▶️ key principles for building a more coherent system.

Read the final reports 🔽
https://t.co/NHCMebY0ef

[LSE Health Policy @LSEHealthPolicy]

Want to learn more about pharmaceutical policy and economics? In a new report commissioned by @HealthFdn #REAL Centre, the Department’s Huseyin Naci & @robinjforrest_ explain pharmaceutical discovery, development, approval and adoption.

➡️ Access here: https://t.co/194uMOrvhc

[JAMA Health Forum @JAMAHealthForum]

Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. @LSEHealthPolicy @PortalResearch @akesselheim @robinjforrest_ https://t.co/GRjfIdodWK

[LSE Health Policy @LSEHealthPolicy]

In new @JAMAHealthForum paper, @LSEHealthPolicy’s Huseyin Naci and @robinjforrest_ examine the insurer restrictions on new drugs in the US Medicare program➡️https://t.co/gYNupVaVAm

@akesselheim @PORTAL_Research

[LSE Phelan US Centre @LSE_US]

Congratulations to our seven PhD Grant Recipients for 2022-23!

Read more about our PhD grants scheme 👇

https://t.co/pDsCwPq2iX

[LSE USAPP blog @LSEUSAblog]

The size of the US pharmaceutical market means that the US Food and Drug Administration has a disproportionately large global influence writes @robinjforrest_ of @LSEHealthPolicy https://t.co/LsaTzQXmk6